These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 26629943

  • 1. Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
    Soni A, Aspinall SL, Zhao X, Good CB, Cunningham FE, Chatta G, Passero V, Smith KJ.
    Oncol Res; 2014; 22(5-6):311-9. PubMed ID: 26629943
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [Abstract] [Full Text] [Related]

  • 7. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.
    Br J Cancer; 2006 Apr 24; 94(8):1122-9. PubMed ID: 16622438
    [Abstract] [Full Text] [Related]

  • 8. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S.
    Clin Drug Investig; 2008 Apr 24; 28(10):645-55. PubMed ID: 18783303
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.
    World J Gastroenterol; 2014 Dec 21; 20(47):17976-84. PubMed ID: 25548497
    [Abstract] [Full Text] [Related]

  • 11. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
    Cancer; 2012 Jun 15; 118(12):3173-81. PubMed ID: 22020739
    [Abstract] [Full Text] [Related]

  • 12. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
    Lin JK, Tan EC, Yang MC.
    Health Qual Life Outcomes; 2015 May 19; 13():61. PubMed ID: 25986478
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.
    Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P, Chilcott J.
    Br J Cancer; 2006 Nov 06; 95(9):1195-201. PubMed ID: 17031407
    [Abstract] [Full Text] [Related]

  • 14. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
    Chen HH, Chen WT, Lee HC, Lin JK, Fang CY, Chou YH, Lin PC, Lin BW, Huang CC, Yeh CH, Hsu HH, Chen HC, Ting WC, Yang MC, Tan EC.
    Qual Life Res; 2015 Feb 06; 24(2):473-84. PubMed ID: 25099199
    [Abstract] [Full Text] [Related]

  • 15. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
    Hsu TC, Wang CC.
    J Comp Eff Res; 2019 Jan 06; 8(2):73-79. PubMed ID: 30560687
    [Abstract] [Full Text] [Related]

  • 16. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H, Cassidy J.
    Expert Rev Anticancer Ther; 2008 Apr 06; 8(4):547-51. PubMed ID: 18402521
    [Abstract] [Full Text] [Related]

  • 17. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z.
    Pharmacoeconomics; 2014 Mar 06; 32(3):235-43. PubMed ID: 23709451
    [Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
    Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL.
    Pharmacoeconomics; 2014 Oct 06; 32(10):1005-13. PubMed ID: 24920195
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.